Study of Homing of Labelled Stem Cells in Human Heart.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the challenges of stem cell therapy is to understand the fate of the injected stem cell. By labelling various stem cells with radioisotopes their fate (homing) can be demonstrated. In this study, we will develop and refine the existing techniques of stem cell labelling to various subtypes of stem cells namely- freshly aspirated bone marrow cells, cryopreserved bone marrow cells, g-csf mobilized peripheral blood stem cells and umbilical cord cells. After testing the labelling efficacy and viability, these cells will be injected in to the coronary arteries of patients with myocardial infarction who have undergone a successful revascularization either by angioplasty or thrombolysis. Homing of stem cells will be demonstrated by nuclear scan after the procedure. We are adapting techniques used to label cells for detection of infection and bleeding using nuclear scans for in vivo scanning. Also we are using Technetium instead of FDG which has very little radioactivity allowing us to work with the current cardiac labs with out having to reconstruct the labs with special shielding for radioactive compounds. Real benefit of stem cells then can be explored after demonstrating the proper homing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cell Therapy in Myocardial Infarction

NCT00350766

Acute Myocardial Infarction

TERMINATED PHASE2/PHASE3

Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery

NCT01267331

Old Myocardial Infarction Chronic Myocardial Ischemia Left Ventricular Dysfunction

UNKNOWN PHASE1/PHASE2

Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.

NCT01536106

Acute Myocardial Infarction

UNKNOWN PHASE1/PHASE2

Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant

NCT02077218

Cancer Survivor Diabetes Mellitus Hypertension

COMPLETED NA

Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery

NCT01625949

Acute Myocardial Infarction

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase One: Four Different types of stem cells will be tested ( Freshly aspirated Bone marrow cells, cryopreserved cells, umbilical cord cells, Stem cells mobilised from bone marrow by g-csf, mesenchymal cells), and the efficacy of labelling documented and effect on viability noted. 3 samples of each type will be tested and the results will be documented. Different cells are being tried to test the efficiency of the labelling technique in different types of cells. This will provide the protocols for all future labelling studies. This will be conducted in collaboration between the stem cell department, nuclear medicine department and nuclear cardiology department.

Phase Two (Clinical Study):

This will be the pilot clinical study done alongside with the phase one study, and will enrol 10 patients with Recent Myocardial infarction ( within 3 months) . A small fraction of patient's own bone marrow stem cells will be labelled with Technetium 99m HMPAO. The labelled cells will be administered via the intracoronary injection along with the unlabeled stem cells. The localization of the radio-labelled stem cells in the myocardium will then be detected using the conventional Gamma camera.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Homing of Stem Cells in the Infarct Area.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental : intracoronary stem cells

intracoronary stem cells will be injected in infarct related artery.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Myocardial Infarction (\< Three Months) with either angioplasty or thrombolysis done to open the infarct causing artery.
* Patent coronary arteries after the infarct
* Left ventricular dysfunction (ejection fraction \< 50%)

Exclusion Criteria

* Ongoing infection
* Obstructive coronary disease
* History of symptoms more than 3 months
* Any evidence of malignancy or other systemic illness.
* Cell yield less than 10 million cells

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Sandeep Seth

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR